Patents by Inventor Ningshao Xia

Ningshao Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140288283
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Application
    Filed: April 8, 2014
    Publication date: September 25, 2014
    Applicants: BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD., XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
  • Patent number: 8748127
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: June 10, 2014
    Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
  • Publication number: 20140147460
    Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 29, 2014
    Applicants: XIAMEN INNOVAX BIOTECH CO. LTD., XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Xianglin Kong, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Publication number: 20140134199
    Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 15, 2014
    Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
  • Patent number: 8715695
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: May 6, 2014
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
  • Patent number: 8603467
    Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: December 10, 2013
    Assignees: Xiamen University, Yang Sheng Tang Company
    Inventors: Yixin Chen, Wenxin Luo, Jun Zhang, Ningshao Xia, Yi Guan, Honglin Chen
  • Publication number: 20130315943
    Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 28, 2013
    Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
  • Publication number: 20130295124
    Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.
    Type: Application
    Filed: July 27, 2010
    Publication date: November 7, 2013
    Applicants: New Jersey Medical School, Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co.,
    Inventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
  • Publication number: 20130230548
    Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
    Type: Application
    Filed: July 1, 2011
    Publication date: September 5, 2013
    Applicant: XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Xiaobing Mo, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Patent number: 8524868
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: September 3, 2013
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
  • Publication number: 20120301449
    Abstract: The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.
    Type: Application
    Filed: August 13, 2012
    Publication date: November 29, 2012
    Applicants: YANG SHENG TANG COMPANY LIMITED, XIAMEN UNIVERSITY
    Inventors: TONG CHENG, TAO ZHANG, YALI ZHANG, JI MIAO, JUN ZHANG, NINGSHAO XIA
  • Publication number: 20110311522
    Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
    Type: Application
    Filed: June 16, 2008
    Publication date: December 22, 2011
    Applicant: XIAMEN UNIVERSITY
    Inventors: Yixin Chen, Wenxin Luo, Jun Zhang, Ningshao Xia, Yi Guan, Honglin Chen
  • Publication number: 20110243904
    Abstract: The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and/or a miRNA and/or a ribozyme and/or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS.
    Type: Application
    Filed: June 2, 2008
    Publication date: October 6, 2011
    Applicants: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Tong Cheng, Tao Zhang, Yali Zhang, Ji Miao, Jun Zhang, Ningshao Xia
  • Publication number: 20100291141
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Application
    Filed: May 29, 2008
    Publication date: November 18, 2010
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
  • Publication number: 20100272751
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Application
    Filed: April 29, 2008
    Publication date: October 28, 2010
    Applicant: BEIJING WANTAI BIOLOGICAL PHARMACY ENTREPRISE CO LTD.
    Inventors: Shaowei Li, Wentong Shen, Zhongyi Li, Minghui Xie, Huirong Pan, Ningshao Xia
  • Publication number: 20100255031
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Application
    Filed: April 29, 2008
    Publication date: October 7, 2010
    Inventors: Ying Gu, Shaowei Li, Minxi Wei, Yangling Xian, Wenxin Luo, Ningshao Xia
  • Publication number: 20100255021
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Application
    Filed: May 29, 2008
    Publication date: October 7, 2010
    Applicants: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
  • Patent number: 7786264
    Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: August 31, 2010
    Assignee: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
    Inventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
  • Publication number: 20100150962
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Application
    Filed: November 9, 2009
    Publication date: June 17, 2010
    Inventors: Ningshao XIA, Jun ZHANG, Shaowei LI, Shengxiang GE, Ying GU, Zhiqiang HE
  • Publication number: 20100143410
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Application
    Filed: September 11, 2009
    Publication date: June 10, 2010
    Inventors: Ningshao XIA, Jun ZHANG, Shaowei LI, Shengxiang GE, Ying GU, Zhiqiang HE